Soleus Capital Management »

Inhibrx Biosciences shares owned by Soleus Capital Management

Quarter-by-quarter ownership of Inhibrx Biosciences (INBX) shares owned by Soleus Capital Management from 13F filings

Historical chart of Soleus Capital Management investment in Inhibrx Biosciences

Tip: Access up to 7 years of quarterly data

All positions including Inhibrx Biosciences held by Soleus Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibrx Biosciences by Soleus Capital Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $1.3M 89k 14.17

More positions owned by Soleus Capital Management

Spdr Ser Tr S&p Biotech Call Option (XBI)
Novocure Ord Shs (NVCR)
Tg Therapeutics (TGTX)
BioMarin Pharmaceutical (BMRN)
Krystal Biotech (KRYS)
Grifols S A Sp Adr Rep B Nvt (GRFS)
Axogen (AXGN)
Iovance Biotherapeutics (IOVA)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Terns Pharmaceuticals (TERN)
Organogenesis Hldgs (ORGO)
Nurix Therapeutics (NRIX)
United Therapeutics Corporation (UTHR)
Celcuity (CELC)
Syndax Pharmaceuticals (SNDX)

View all positions for Soleus Capital Management

Top funds holding Inhibrx Biosciences

Viking Global Investors
Perceptive Advisors
BlackRock
HighTower Advisors
Vanguard Group
Walleye Trading Advisors
Sofinnova Ventures
Slotnik Capital
Millennium Management
Geode Capital Management
Caption Management
Castalian Partners
State Street Corporation
Kennedy Capital Management
Arrowpoint Asset Management

View all funds holding Inhibrx Biosciences